Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & Fibrosis Development.
Target Overview & Key Facts
MMP-9 (Matrix Metalloproteinase 9, Gelatinase B) is a zinc-dependent endopeptidase that degrades type IV collagen, a key component of the extracellular matrix. It is implicated in cancer metastasis, fibrosis, and inflammation. Key structural features include three Fibronectin type-II domains (Fibronectin type-II 1, 2, 3) that mediate substrate binding and are essential for gelatinase activity. Single nucleotide polymorphisms (SNPs) in MMP-9 are associated with disease susceptibility: rs1805088 (Q279R), rs41427445 (R574L), and rs1805089 (R668Q) have been documented in UniProt (P14780).
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MMP-9 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MMP-9 Pro-Form & Active-Form Recombinant Protein (Full-Length / Catalytic Domain). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. Includes Pro-domain intact or APMA-activated forms. | View MMP-9 Products |
| Gene Delivery | MMP-9 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. Includes WT and catalytic mutant (E402Q). | View MMP-9 Products |
| Benchmark Ab | Anti-MMP-9 (Andecaliximab Biosimilar Sequence). Recombinant positive control for binding and inhibition assays. Hemopexin domain binder. | View MMP-9 Products |
| Validator | MMP-9 siRNA Set. For knockdown verification and specificity controls in cell-based assays. | View MMP-9 Products |
| Selectivity Panel | MMP-2 (Gelatinase A). Closest homolog; crucial for counter-screening to avoid off-target musculoskeletal effects. | View MMP-2 Products |
| Regulatory Target | TIMP-1. Natural endogenous inhibitor; required for enzyme-inhibitor complex and activation assays. | View TIMP-1 Products |
| Activator | MMP-14 (MT1-MMP). Key physiological activator of pro-MMP-9; necessary for cascade mechanism studies and TME remodeling. | View MMP-14 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval for toxicology | Human/Mouse/Cyno MMP-9 ortholog proteins available with >95% purity; Sequence Verified. Matched buffer formulations. |
| Subfamily selectivity (avoid MMP-1/8 inhibition) | Homolog panel proteins (MMP-1, -2, -3, -14) strictly verified by mass spec; sequence divergence mapped. |
| Pro- vs Active-form discrimination | Latent Pro-MMP-9 (intact propeptide) and APMA-activated Active-MMP-9 with confirmed catalytic activity via FRET substrate (DQ-gelatin). |
| Catalytic vs Hemopexin domain targeting | Domain-truncated variants (catalytic domain only, hemopexin domain only) for epitope mapping. |
| Lack of positive controls | Clinical Benchmark Antibodies (Andecaliximab biosimilar sequence) included; Catalytic-dead mutant (E402Q) for binding controls. |
| False positives / Off-target inhibition | Validated siRNA included for specificity checks in cell-based gelatin zymography. |
Global Clinical Landscape & Future Outlook
The MMP-9 inhibitor landscape has shifted dramatically following the failure of first-generation broad-spectrum MMP inhibitors (Marimastat, Periostat) which caused dose-limiting musculoskeletal syndrome via off-target MMP-1 and MMP-8 inhibition. The current therapeutic paradigm demands absolute selectivity for MMP-9 over collagenases. Second-generation approaches leverage the unique S1' specificity pocket of MMP-9 and hemopexin domain targeting to avoid zinc-chelating mechanisms. Andecaliximab (anti-MMP-9 mAb) completed Phase III evaluation in gastric cancer; the field now pivots toward inflammatory indications (ulcerative colitis, idiopathic pulmonary fibrosis) and combinations with immune checkpoint inhibitors. Emerging modalities include conditionally active biologics, MMP-9-cleavable ADC linkers, and allosteric inhibitors targeting non-catalytic sites.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | AstraZeneca (AZD1236), Insmed, multiple biotechs | COPD, IPF, Metastatic Cancer | Selectivity Panel Assay (need MMP-1/2/3/14 proteins to confirm >100-fold selectivity) |
| Monoclonal Antibody | Gilead (Andecaliximab), potential new entrants | Gastric Cancer, IBD, Solid Tumors | Hemopexin domain binding (need full-length active protein with correct disulfide bonds) |
| siRNA / Gene Therapy | Alnylam (early research), academic institutions | Fibrosis, Solid Tumors | Cell-based knockdown validation (need lentivirus and siRNA combo) |
| ADC Cleavable Linkers | Next-gen oncology pipelines | Solid Tumors | Enzymatic cleavage assay (need active MMP-9) |
Live MMP-9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Strategic Insights for Researchers
MMP-9 drug development requires careful attention to selectivity (vs MMP-2, MMP-1), enzyme form (pro vs active), and domain targeting (catalytic vs hemopexin). The availability of high-quality recombinant proteins—including orthologs, mutants (E402Q), and domain-truncated variants—is critical for robust assay development and mechanism studies.